|
Press Releases |
|
 |
|
Monday, August 1, 2016 |
|
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out |
Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the MeMAMORIO1 tracking tool to support people with dementia going out. more info >> |
|
Friday, July 22, 2016 |
|
Eisai Receives Positive CHMP Opinion on New Indication for Anticancer Agent Lenvatinib in Combination with Everolimus for Treatment of Advanced Renal Cell Carcinoma |
Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate in combination with everolimus. more info >> |
|
Wednesday, July 20, 2016 |
|
U.S. FDA Approves BELVIQ XR, A Once-Daily Formulation of Lorcaserin for Chronic Weight Management |
Eisai Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for BELVIQ XR, a once-daily formulation of lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ) for chronic weight management. more info >> |
|
Thursday, June 30, 2016 |
|
Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. more info >> |
|
Monday, June 20, 2016 |
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
Thursday, June 16, 2016 |
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
Friday, June 3, 2016 |
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
Wednesday, June 1, 2016 |
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
Wednesday, May 25, 2016 |
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
Tuesday, May 24, 2016 |
|
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting |
Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Ditchit Detonates Iconic Twitter Bird to Symbolize Launch of Local Marketplace
Jun 21, 2025 06:00 HKT/SGT
|
|
|
Shaping a New Platform for Global Growth Discussed at Open Dialogue within SPIEF-2025
Jun 20, 2025 23:00 HKT/SGT
|
|
|
Global Economic Shifts in Focus as Madrid Professor Addresses SPIEF 2025 Opening Session
Jun 20, 2025 23:00 HKT/SGT
|
|
|
QS Energy Receives Initial Order for Multi-Year AOT Technology Deployment
Jun 20, 2025 21:00 HKT/SGT
|
|
|
BW Digital and BW ESS launch BW Velora to drive greater digital sustainability
Jun 20, 2025 19:40 HKT/SGT
|
|
|
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health
Jun 20, 2025 19:06 JST
|
|
|
New method to blend functions for soft electronics
Jun 20, 2025 15:00 HKT/SGT
|
|
|
Legacy and Lifestyle: U.S. Polo Assn. Hosts Iconic Party at Pitti Uomo 108 in Florence, Italy
Jun 19, 2025 22:30 HKT/SGT
|
|
|
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
|
|
|
CleverTap Launches 'Promos' - The Industry-First All-In-One Rewards Management Platform
Jun 19, 2025 10:19 HKT/SGT
|
|
|
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
|
|
|
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Jun 19, 2025 09:15 HKT/SGT
|
|
|
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 9:30 JST
|
|
|
Euro Manganese and Integrals Power Sign LOI and Offtake Term Sheet to Strengthen LMFP Battery Supply Chain
Jun 19, 2025 06:59 HKT/SGT
|
|
|
Data Turing Launches to Automate Brand Reputation Using Verifiable Truth
Jun 18, 2025 22:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|